| 000 | 03119cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223032252.0 | ||
| 008 | 190502s2018 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.11.29.Ph.D.2018.Os.P | ||
| 100 | 0 | _aOsama Mohamed Abutaleb | |
| 245 | 1 | 0 |
_aPossible effects of exenatide on osteoporosis, depression and myocardial infarction experimentally induced in adult female albino rats / _cOsama Mohamed Abu Taleb ; Supervised Nahed Mahmoud Moussa , Hesham Attia Awad , Rahma Kamal Eldine Abou Elnour |
| 246 | 1 | 5 | _aالتأثيرالمحتمل للاكزيناتيد علي هشاشة العظام و الاكتئاب و جلطة القلب المحدثين معمليا في إناث الجرذان البيضاء البالغة |
| 260 |
_aCairo : _bOsama Mohamed Abutaleb , _c2018 |
||
| 300 |
_a149 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Pharmacology | ||
| 520 | _aBackground: Post-menopausal females are categorized as a high risk group for osteoporosis, depression and major cardiovascular events. Although several drugs are currently used for treatment of depression, these drugs are known to alleviate the symptoms but have some limitations owing to their severe side effects and their cardioprotective effects are not well established. Consequently, looking for new agents that are equally or more effective and cause fewer side effects is urgently needed. The aim of this work: was to study the possible protective and therapeutic effects of exenatide on experimentally induced osteoporosis, depression and myocardial infarction in adult ovariectomized female albino rats. Methods: Forty eight mature female albino rats, matched for age and weight (150-250 gm) were used. Osteoporosis and depression were experimentally induced by bilateral ovriectomy (OVX) and leaving the animals for 6 weeks without treatment. Rats were divided into 4 groups.Group-I (Sham group) was exposed to Sham opertion, ovariectomized (OVX) group-II [OVX non treated], prophylactic exenatide group-III (received prophylactic exenetide (1og/kg/d SC) for 6 weeks following OVX) and group IV (OVX + treatment for 8 weeks). Group IV was sudivided into 3 subgroups, group-IVa (treated by vitamin D 0.25æg/day orally for 5 days per week), IVb (treated by fluoxetine 10 mg/kg/day orally) and IVc (treated by exenatide1og/kg/d SC). Assesment of depression was done by recording active swimming time (AST) in forced swimming test (FST) and, ambulation score (AS) and rearing number (RN), in open field tests OFT | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aDepression | |
| 653 | 4 | _aMyocardial infarction | |
| 653 | 4 | _aOsteoporosis | |
| 700 | 0 |
_aHesham Attia Awad , _eSupervisor |
|
| 700 | 0 |
_aNahed Mahmoud Moussa , _eSupervisor |
|
| 700 | 0 |
_aRahma Kamal Eldine Abou Elnour , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c71730 _d71730 |
||